Sean Khozin, MD, MPH, a physician-executive, board-certified oncologist, and data scientist with over 15 years of experience in therapeutic development, drug regulation, and the applications of artificial intelligence and machine learning in biomedical research.
As the founder of Phyusion, Dr. Khozin is working on advancing innovations at the intersection of biology, technology, and artificial intelligence. He is the former Chief Executive Officer of CancerLinQ, a precision oncology enterprise focused on transforming cancer care and research with real-world data and advanced analytics. He was previously the Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, leading a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative new medicines and vaccines. Prior to this, he was a founding member of the US FDA’s Oncology Center of Excellence and Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator that he established under special federal authorities. As a uniquely entrepreneurial sandbox housed within the agency responsible for regulating nearly a third of the US economy, INFORMED played a pivotal role in shaping the US FDA’s position on real-world evidence and catalyzing the use of novel data science solutions in drug discovery and clinical development.
Before his tenure in the US federal government, Dr. Khozin was the cofounder of Hello Health, a pioneering TechBio company developing telemedicine, point-of-care data visualization, and advanced analytical systems as an integrated approach to optimizing drug discovery, patient care, and clinical research. The company’s core technology offerings were first operationalized in a multidisciplinary network of clinics he had founded called SKMD.
Dr. Khozin is a Research Affiliate at the MIT Laboratory for Financial Engineering, where he combines his quantitative and life sciences expertise in support of novel solutions for improving the lives of patients with high unmet medical need. He has over a decade of clinical and basic science research experience at the US National Cancer Institute, having started his clinical work developing new molecular profiling methods in thoracic malignancies.